CTLA-4 blocker therapy, despite documented activities in concomitant activation, can also deplete regulatory T cells (Treg) from the tumor microenvironment (TME) as a result of high CTLA-4 expression at the Treg level [16]. This evidence concerns the gene CTLA4 and neoplasm.